Clinical Study

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma

Ahmad M. Mansour, 1 J. Fernando Arevalo, 2,3 Eman Al Kahtani, 2
Hernando Zegarra, 4 Emad Abboud, 2 Rajiv Anand, 5 Hamid Ahmadieh, 6 Robert A. Sisk, 7
Salman Mirza, 8 Samuray Tuncer, 9 Amparo Navea Tejerina, 10 Jorge Mataix, 10
Francisco J. Ascaso, 11 Jose S. Pulido, 12 Rainer Guthoff, 13 Winfried Goebel, 14
Young Jung Roh, 15 Alay S. Banker, 16 Ronald C. Gentile, 17 Isabel Alonso Martinez, 18
Rodney Morris, 19 Neeraj Panday, 20 Park Jung Min, 21 Emilie Mercé, 22 Timothy Y. Y. Lai, 23
Vicky Massoud, 1 and Nicola G. Ghazi 2

1 Departments of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, P.O. Box 113-6044, Beirut, Lebanon
2 Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
3 Wilmer Eye Institute, The Johns Hopkins University, Baltimore, MD 21287, USA
4 Retina Associates of Cleveland, 3401 Enterprise Parkway, Suite 300, Beachwood, OH 44122, USA
5 Texas Retina Associates, University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
6 Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Labbafinejad Medical Center, Tehran, Iran
7 Cincinnati Eye Institute, Cincinnati, OH 45212, USA
8 Birmingham Midland Eye Centre, Dudley Road, Birmingham B187QH, UK
9 Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Sergül Sokak Saralı Sitesi, A2 3 Gayrettepe, 34349 İstanbul, Turkey
10 Fundación Oftalmológica del Mediterráneo, 46015 Valencia, Spain
11 Department of Ophthalmology, “Lozano Blesa” University Clinic Hospital, School of Medicine, University of Zaragoza, 50001 Zaragoza, Spain
12 Mayo Clinic, 200 1st Avenue South West Rochester, Minnesota, MN 55902, USA
13 University-Eye Hospital Düsseldorf, Moorstraße 5, 40225 Düsseldorf, Germany
14 Department of Ophthalmology, University of Wuerzburg, 97080 Wuerzburg, Germany
15 Department of Ophthalmology, St. Mary’s Hospital, Catholic University of Korea, Seoul 137-701, Republic of Korea
16 Banker’s Retina Clinic and Laser Centre, 5 Subhash Society, Behind Ishvar Bhuvan, Ahmedabad, Gujarat 380009, India
17 Department of Ophthalmology, New York Eye and Ear Infirmary, New York, NY 10014, USA
18 Martinez Center, Avenida Maria Guerrero 144, Leganés Norte, 28919 Madrid, Spain
19 Department of Retina and Vitreous, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore, Tamil Nadu 641044, India
20 MM Joshi Eye Institute, Gokul Road, Hosur, Hubli, Karnataka 580021, India
21 Maryknoll Medical Center, 4-12 Daecheon-dong, Jung-gu, Busan 600-730, Republic of Korea
22 Service d’Ophthalmologie, CHU Dupuytren, 87042 Limoges, France
23 Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong

Correspondence should be addressed to Ahmad M. Mansour; ammansourmd@gmail.com

Received 27 April 2014; Accepted 5 July 2014; Published 23 July 2014

Academic Editor: Takayuki Baba

Copyright © 2014 Ahmad M. Mansour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 19.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.

1. Introduction

Choroidal osteoma is a rare ossifying choroidal tumor involving mostly young healthy females in the second decade of life [1–6]. The benign mass appears as a deep yellowish lesion with distinct geographic borders at the juxtapapillary or macular region, with branching “spider” vessels on its surface. The diagnosis is confirmed with the presence of calcification on ultrasonography and computed tomography. Vision is often compromised by gradual atrophy of the overlying retina [6] or by accumulation of either subretinal fluid or subretinal hemorrhage with or without choroidal neovascularisation (CNV). Frequent exams are recommended for patients with choroidal osteoma for early detection of a subretinal neovascular membrane and potential treatment. Therapies have included laser photocoagulation [7, 8], excision of CNV [9], photodynamic therapy (PDT) [10–14], and transpupillary thermal therapy (TTT) [15, 16].

We evaluated clinically and by optical coherence tomography (OCT) [6, 17] the role of intravitreal injections of vascular endothelial growth factor (VEGF) antagonist in the therapy of CNV in choroidal osteomas after their use in some case reports [18–29].

2. Materials and Methods

We reviewed retrospectively the files of subjects having choroidal osteoma who were treated with intravitreal injections of bevacizumab or ranibizumab for active CNV. Intravitreal injections of 0.05 mL or 0.1 mL of either bevacizumab (25 mg/mL) or ranibizumab (10 mg/mL) were administered in the office as 3 initial consecutive doses or based on OCT response depending on physician preference. Intravitreal injection was performed using a 30-gauge needle in a sterile manner after topical anesthesia and povidone instillation in the lower conjunctival sac. Bevacizumab (Avastin, Genentech Inc, San Francisco, CA) aliquots were prepared in the hospital pharmacies of the corresponding institutions. Ranibizumab (Lucentis, Genentech Inc, San Francisco, CA) was also used in some centers. A standardized spreadsheet was used to collect the clinical data. Photodynamic therapy (PDT) with intravenous verteporfin (standard dose 6 mg/m² body surface area or half the standard dose) (Visudyne, Novartis AG, Basel, Switzerland) was administered simultaneously in some patients based solely on individual physician preference. Institutional review board/ethics committee approval and patients’ signed informed consents were obtained for this study. In addition, this study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki for research involving human subjects. The offlabel use of both drugs and their potential risks and benefits was discussed extensively with all patients. Best corrected visual acuity (BCVA) was assessed using either ETDRS or Snellen charts and listed as logarithm of the minimum angle of resolution (logMAR) equivalents. Retreatment was done when there was recurrent activity evaluated by fundus examination, fluorescein angiography (leakage, growth of CNV), or optical coherence tomography. Differences between final and initial BCVA were tested using paired Student t-test. Improvement of visual acuity was defined as any fraction of a line of improvement on the ETDRS chart. We did not compare the initial to the posttreatment central foveal thickness because of the different OCT machines among centers as well as because of the need for thickness analysis by gender, race, age, and refractive status [17]. We analyzed only the absolute decrease in central foveal thickness. One patient had bilateral osteoma with CNV arising in one eye and several years later in the fellow eye and hence both eyes were included in the statistical analysis. Significance was set at the 0.05 level. We used SPSS 19 version for statistical calculation (IBM, Armonk, New York, 2010). Literature review till April 2014 (using both PubMed and Google Scholar) was added to ascertain the visual results in this rare disease entity with bevacizumab or ranibizumab therapies [18–29]. Collaborators and one of us (AMM) measured the CNV size on digital fluorescein transit films and the osteoma basal diameter on color films in reference to the horizontal disc diameter by using a transparent reticule or ruler on the computer screen.

3. Results

We treated 26 eyes from 25 patients with a mean age at presentation of 29 years (range 8–57 years) with 16 women and 9 men having the following racial distribution: 18 Caucasians, 4 Indians, and 3 Asians. Laterality included 15 right eyes (57.7%) and 11 left eyes (42.3%) (Table 1). Mean follow-up was 26 months (range 6–71 months, median 20 months). The longest osteoma basal diameter varied from 1 to 10 disc diameters with a mean of 4.6 disc diameters. Bevacizumab was injected in 17 eyes (65.4%), ranibizumab in 5 eyes (19.2%), and a combination of both drugs in 4 eyes (15.4%). The volume injected was 0.05 mL in 24 eyes (92.3%) and 0.1 mL in 2 eyes (7.7%). The mean number of injections was 4.5 (range 1–17, median 3) at the last follow-up. The mean number of injections at 6 months, 12 months, and 24 months was, respectively, 2.4 (n = 26), 3.2 (n = 20), and 5.5 (n = 13). CNV was subfoveal in 14 eyes (53.8%), juxtafoveal in 5 eyes (19.2%), extrafoveal in 5 eyes (19.2%), and peripapillary in 2 eyes (7.7%). The mean size of CNV was 1.3 disc diameter
Table 1: Clinical profile of 26 eyes of 25 cases from the Collaborative Choroidal Osteoma Group*.

| Case No. | Age (y) | Gender | Osteoma Location | CNV Location | Initial Vision | Final Vision | Initial CFT | 6-month CFT | Type of Injection | Follow-up (month) | Number of Injection |
|----------|---------|--------|------------------|--------------|----------------|--------------|-------------|-------------|------------------|------------------|-------------------|
| 1        | 34      | F      | Subfoveal        | Juxtafoveal  | 20/300 (6/90) | 20/60 (6/18) | NA          | 174         | Bevacizumab      | 18               | 2                 |
| 2        | 37      | M      | Posterior pole   | Subfoveal with blood | 20/25 (6/7.5) | 20/20 (6/6) | NA          | NA          | Bevacizumab      | 52               | 8                 |
| 3        | 43      | F      | Subfoveal        | Subfoveal with blood | 20/32 (6/9.5) | 20/100 (6/30) | 294         | 197         | Ranibizumab      | 18               | 1                 |
| 4        | 8       | F      | Subfoveal        | Subfoveal with blood | CF             | 20/40 (6/12) | 434         | NA          | Bevacizumab      | 24               | 2                 |
| 5        | 28      | M      | Subfoveal        | Subfoveal with SRF | 20/60 (6/18) | 20/80 (6/24) | 373         | 252         | Bevacizumab      | 46               | 3                 |
| 6        | 13      | F      | Subfoveal        | Subfoveal with blood | 20/100 (6/30) | 20/50 (6/15) | 307         | 212         | Ranibizumab      | 42               | 3                 |
| 7        | 27      | M      | Superotemporal arcade | Extrafoveal with blood | 20/80 (6/24) | 20/30 (6/9) | NA          | NA          | Ranibizumab      | 18               | 7                 |
| 8        | 27      | F      | Subfoveal        | Extrafoveal    | 20/30 (6/9) | 20/20 (6/6) | 264         | 207         | Bevacizumab      | 12               | 1                 |
| 9        | 46      | F      | Subfoveal        | Subfoveal with blood | 20/300 (6/90) | 20/80 (6/24) | 244         | NA          | Bevacizumab      | 60               | 8                 |
| 10       | 37      | F      | Posterior pole   | Peripapillary  | 20/80 (6/24) | 20/20 (6/6) | 790         | 360         | Bevacizumab      | 26               | 4                 |
| 11       | 28      | F      | Posterior pole   | Peripapillary  | 20/400 (6/120) | 20/400 (6/120) | Highly elevated serous macular detachment | Highly elevated serous macular detachment | Ranibizumab | 8               | 2                 |
| 12       | 48      | F      | Subfoveal & juxtafoveal | Subfoveal & juxtafoveal | 20/40 (6/12) | 20/20 (6/6) | 298         | 306         | Ranibizumab number 5, Bevacizumab number 10 | 35               | 15                |
| 13       | 25      | F      | Subfoveal        | Subfoveal    | 20/80 (6/24) | 20/20 (6/6) | 203         | 166         | Ranibizumab      | 15               | 1                 |
| 14       | 33      | F      | Subfoveal        | Subfoveal    | (20/67) 6/20 | (20/320) 6/95 | 316         | 207         | Bevacizumab      | 24               | 3                 |
| 15       | 22      | M      | Subfoveal        | Juxtafoveal  | CF 1m     | CF 2m     | NA          | 675         | Bevacizumab      | 7                | 3                 |
| 16       | 41      | F      | Juxtafoveal      | Juxtafoveal  | 20/200 (6/60) | 20/200 (6/60) | 427         | 258         | Ranibizumab number 3, Bevacizumab number 1 | 6                | 4                 |
| 17       | 24      | M      | Extrafoveal      | Extrafoveal with blood | 20/60 (6/18) | 20/30 (6/9) | 350         | 210         | Bevacizumab      | 54               | 17                |
| 18       | 14      | M      | Subfoveal        | Subfoveal with blood | CFNF       | CFNF      | >1000       | >500        | Bevacizumab number 4, Ranibizumab number 5 | 26               | 9                 |
| 19       | 35      | F      | Posterior pole   | Peripapillary | 20/70 (6/21) | 20/40 (6/12) | 600         | 400         | Bevacizumab      | 12               | 2                 |
| Case N. | Age  | Gender | Osteoma location | CNV location | Initial vision | Final vision | Initial CFT | 6-month CFT | Type of injections | Follow-up (month) | Number of injection | Osteoma longest dimension (disc diameter) |
|---------|------|--------|------------------|--------------|----------------|--------------|-------------|-------------|-------------------|-------------------|-------------------|----------------------------------------|
| 20      | 45   | M      | Subfoveal        | Juxtafoveal  | 20/63 (6/19)   | 20/32 (6/9.5) | 237         | 222         | Bevacizumab       | 6                 | 2                 | 1.2                     |
| 21      | 13   | F      | Subfoveal        | Subfoveal    | 20/200 (6/60)  | 20/63 (6/9.5) | 339         | 249         | Bevacizumab       | 6                 | 2                 | 4                      |
| 22      | 20   | M      | Subfoveal        | Juxtafoveal  | 20/70 (6/21)   | 20/40 (6/12)  | 282         | 171         | Bevacizumab       | 71                | 1                 | 4                      |
| 23      | 22   | M      | Subfoveal        | Subfoveal    | 20/160 (6/48)  | 20/250 (6/75) | 427         | 225         | Bevacizumab       | 46                | 5                 | 4.9                     |
| 24      | 11   | M      | Juxtafoveal      | Extrafoveal  | 20/20 (6/6)    | 20/20 (6/6)  | NA          | NA          | Bevacizumab       | 16                | 3                 | 3.4                     |
| 25      | 57   | F      | Subfoveal        | Subfoveal    | 20/800 (6/240) | 20/30 (6/9)  | NA          | 283         | Ranibizumab number 3 Bevacizumab number 3 | 21                | 6                 | 4                      |
| 26      | 25   | F      | Extrafoveal      | Subfoveal    | 20/300 (6/90)  | 20/100 (6/30) | 360         | 320         | Bevacizumab       | 12                | 2                 | 6                      |

*N = number; CFT = central foveal thickness; SRF = subretinal fluid; F = female; M = male; NA = not available; CF = counting fingers; CFNF = finger counting at near face.*
By paired comparison, the mean decrease from baseline was a decrease in central foveal thickness at 6 months of therapy. At 1 year (n = 11 intraocular injection, 320 microns at baseline, 339 microns (n = 20 eyes) at 6 months after therapy (PDT, leaving 18 eyes for analysis). Visual acuity improved from 0.77 (6/35 or 20/118) to 0.44 (6/17 or 20/55) at 6 months (P = 0.01) at 1 year, and 0.77 at 2 years. No ocular or systemic adverse events were noted.

To analyze the effect of anti-VEGF alone (without PDT) in more or less acute cases with CNV, we eliminated 2 eyes that had chronic signs of CNV (atrophic thin retina, very large attenuation and disruption of the retinal pigment epithelium–Bruch membrane complex overlying the choroidal osteoma) and 6 eyes that had comitant PDT, leaving 18 eyes for analysis. Visual acuity improved from 0.77 (6/35 or 20/118) to 0.44 (6/17 or 20/55) at 6 months (n = 18) (P = 0.006), a gain of 3.3 lines (Table 2). Thirteen eyes (50.0%) had improvement in BCVA, 2 eyes (7.7%) had stable vision, and 3 eyes (11.5%) had loss of vision at the 6-month follow-up. Also, there was visual improvement of 3.4 lines at 1 year (0.67 to 0.34; n = 14; P = 0.01) and 4.9 lines at 2 years (0.79 to 0.30; n = 7; P = 0.03). Moreover, by paired comparison, the decrease in central foveal thickness from baseline was 139.5 microns at 6 months (n = 11; P = 0.002), 123.7 microns at 12 months (n = 6; P = 0.1), and 196.4 microns at 24 months (n = 5; P = 0.1). In the other group of concomitant PDT, BCVA improved by 3.9 lines at the 6-month follow-up from 0.65 (6/27 or 20/90) to 0.26 (6/11 or 20/36) (P = 0.04) (Table 3). In addition, Table 4 details the characteristics of 13 cases of choroidal osteomas treated with anti-VEGF injections published in the literature.

4. Discussion

Visual impairment in eyes with choroidal osteoma can be attributable to several factors including subfoveal location, foveal edema, photoreceptor degeneration [6], serous retinal detachment, and CNV [3]. Without any therapy, choroidal osteoma-associated CNV can result in a progressive and permanent loss of visual acuity. CNV occurs in 31% to 47% of patients followed for 10 years [3, 6]. The cause for the development of a CNV in eyes with a choroidal osteoma has not been determined, but choroidal osteomas with overlying hemorrhage or irregular surface appeared at higher risk of developing a CNV [3]. Osteomas, in general, have a high bone turnover reflecting their high metabolic rate and hence may steal blood supply from adjacent tissues, especially overlying retinal pigment epithelium which may upregulate the expression of VEGF. Presumably, attenuation and disruption of the retinal pigment epithelium-Bruch membrane complex overlying the choroidal osteoma allows over years for the development of CNV.

There is no standard treatment for a choroidal osteoma. Various treatments for CNV have been tried, but they do not usually halt visual loss. The results of one study showed that photocoagulation of an extrafoveal classic CNV was successful in closing CNV in 25% of treated eyes [2]. However, photocoagulation can stimulate rapid vascular remodeling and anastomoses in choroidal osteoma [3]. Another study reported that the CNV can be surgically removed, but
Table 4: Literature review of 13 choroidal new vessels associated with choroidal osteomas treated with intravitreal anti-VEGF injections.*

| Author                      | Age | Gender | Osteoma location & longest dimension | CNV location | Initial vision | Final vision | Initial CFT (microns) | Final CFT (microns) | Type & number of injections | Follow-up (month) | Details                                                                 |
|-----------------------------|-----|--------|--------------------------------------|--------------|----------------|--------------|------------------------|----------------------|---------------------------|-----------------|-------------------------------------------------------------------------|
| Ahmadieh and Vafi [18]      | 19  | F      | Juxtafoveal 3DD OD                  | Juxtafoveal  | 6/60           | 6/7.5        | 544                    | 240                  | One 1.25 mg bevacizumab  | 9 (regression of CNV) | (reduction of CNV)                                                   |
| Narayanan and Shah [19]     | 25  | F      | Peripapillary OS                    | Subfoveal    | CF 1.5 m       | 6/35         | NM                     | NM                   | Two 1.25 mg bevacizumab | 4 (regression of CNV) | (reduction of CNV)                                                   |
| Shields et al. [20]         | 34  | F      | Subfoveal 7DD OD                    | Subfoveal    | 6/30           | 6/9          | NM                     | NM                   | One 1.25 mg bevacizumab & three 0.5 mg ranibizumab | 6 (fibrotic CNV with flat macula) |
| Song et al. [21]            | 24  | M      | Peripapillary 2.5DD                  | Subfoveal    | CF 20 cm       | 6/60         | NM                     | NM                   | Two 1.25 mg bevacizumab | 10; prior to PDT | (reduction of CNV)                                                   |
| Song and Roh [22]           | 43  | F      | Subfoveal 4DD OS                    | Subfoveal    | 6/60           | 6/30         | NM                     | NM                   | One 0.5 mg ranibizumab | 6 (reduction of CNV) | (reduction of CNV)                                                   |
| Rao and Gentile [23]        | 24  | M      | Subfoveal 2DD OS                    | Subfoveal    | 6/18           | 6/9          | NM                     | NM                   | Three 1.25 mg bevacizumab | 5               | (reduction of CNV)                                                   |
| Ayachit et al. [24]         | 27  | F      | Peripapillary 3DD OD                | Juxtafoveal  | 6/75           | 6/6          | NM                     | NM                   | One bevacizumab (dose NM) | 6 (regression of CNV) | (reduction of CNV)                                                   |
| Kubota-Taniæi et al. [25]   | 12  | F      | Peripapillary 3DD OS                | Extrafoveal  | 6/30           | 6/9          | NM                     | NM                   | Two 1.25 mg bevacizumab | 48 (regression of CNV) | (reduction of CNV)                                                   |
| Salehipour et al. [26]      | 19  | F      | NM                                   | NM           | NM             | NM           | NM                     | NM                   | Two 1.25 mg bevacizumab | 7               | (reduction of CNV)                                                   |
| Wu et al. [27]              | 46  | F      | Subfoveal OS                         | Subfoveal    | 6/30           | 6/12         | 116 micron flattening | Two 1.25 mg bevacizumab | 23 (fibrosis of CNV) | (fibrosis of CNV) | (reduction of CNV)                                                   |
| Wu et al. [27]              | 57  | F      | Peripapillary 10DD OD               | Subfoveal    | 6/240          | 6/9          | NM                     | NM                   | Three 0.5 mg ranibizumab | 14 (fibrosis of CNV) | (fibrosis of CNV)                                                   |
| Carle et al. [28]           | 20  | M      | Macular OD                           | Occult       | 6/24           | 6/12         | NM                     | NM                   | Six 1.25 mg bevacizumab | 13              | (fibrosis of CNV)                                                   |
| Erol et al. [29]            | 28  | F      | Peripapillary and macular 4DD OD    | Subfoveal    | 6/120          | 6/24 after first injection and then 6/60 after second injection | NM | NM | Two 0.5 mg ranibizumab | 2 (Tear of the retinal pigment epithelium after ranibizumab injection) |

*VEGF = vascular endothelial growth factor; CNV = choroidal neovascularization; CFT = central foveal thickness in microns; DD = disc diameter; NM = not mentioned; OD = right eye; OS = left eye; M = male; F = female; PDT = photodynamic therapy.
the postoperative visual acuity was poor at 6/95 (20/320) [4]. PDT has been partially successful in treating CNV in eyes with choroidal osteoma. Earlier studies showed that, 6 months after a single PDT, the metamorphopsia can resolve completely; in one study, the visual acuity was not changed [5] and in another study it improved from 6/60 (20/200) to 6/6 (20/20) [6]. Another study reported that four PDT applications led to closure of the CNV, but the final vision was 6/35 (20/120) [7]. PDT has successfully caused closure of extrafoveal CNV in choroidal osteoma [6]. Laser photocoagulation or PDT in choroidal osteomas with or without CNV may carry the risk of decalcification of choroidal osteoma [10]. Shields et al. [10] proposed that photodynamic therapy could be a therapeutic modality for choroidal neovascularization and induction of decalcification of extrafoveal osteoma to prevent tumor growth into the foveola. However, these results should not be extrapolated to subfoveal choroidal osteoma because decalcification of subfoveal choroidal osteoma could result in worse visual acuity because of loss of retinal pigment epithelium and choroidal perfusion [1, 3, 6, 10].

TTT was effective in obstructing the CNV but the visual outcome was also poor. An earlier report indicates that, at 10 months after one TTT application, vision improved from 6/24 (20/80) to 6/18 (20/60), and the vision was maintained with a scarred CNV [8]. In another report, the final visual acuity was 6/60 (20/200) after three TTT applications [9]. Combination therapy of PDT and anti-VEGF injections reduced the number of anti-VEGF injections, hence reducing the risk of vision-threatening complications. The reduction in the number of injections was marginal in the current series (Table 2) and there was little difference between the use of PDT or its omission, although a direct comparison could not be done because of the small number in the current series as well as difference in protocols in administration of both anti-VEGF agents and PDT.

Ahmadieh and Vafi [18] reported the dramatic response of a juxtafoveal CNV associated with choroidal osteoma to a single intravitreal injection of bevacizumab in a 19-year-old female with visual improvement from 6/60 (20/200) to 6/7.5 (20/25) and resolution of metamorphopsia with the treatment effect persisting during a 9-month follow-up period. Subsequently, the positive effects of intravitreal anti-VEGF injections were confirmed in 10 cases with CNV associated with choroidal osteoma (Table 4). Kubota-Taniai et al. [25] described the long-term effect of 2 intravitreal bevacizumab injections (4 months apart) in complete angiographic regression of CNV for a period of 4 years in a 12-year-old girl with visual improvement from 6/30 (20/100) to 6/9 (20/30). We noted similar response in 8 out of 26 eyes needing only 1 to 2 injections with maintenance of visual improvement. It is possible that small osteomas or osteoma that do not grow do not need further injections. This issue was not studied in the current protocol. The growth of the tumor during followup was not assessed also and it could be that growing tumors secrete more VEGF and require more injections. The young age of the patients with osteoma may partly explain the good response to anti-VEGF therapies. A single case had retinal pigment epithelial tear after anti-VEGF injection [29].

5. Conclusions

The inherent limitations of this study include its small number, retrospective nature, limited follow-up, lack of a standard therapeutic protocol, lack of a control group, and difference in OCT machines among centers. However, our results suggest that intravitreal bevacizumab or ranibizumab might be an effective therapeutic option for choroidal osteoma-associated CNV that is causing deterioration in vision, particularly when the CNV is juxtafoveal or subfoveal in location. In eyes where the CNV is not subfoveal, adjunctive therapies such as laser photocoagulation or PDT could be considered. Further studies with longer follow-up are indicated to confirm the long-term efficacy of bevacizumab or ranibizumab monotherapy in choroidal osteomas.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] C. L. Shields, J. A. Shields, and J. J. Auggsburger, "Choroidal osteoma," Survey of Ophthalmology, vol. 33, no. 1, pp. 17–27, 1988.
[2] G. W. Aylward, T. S. Chang, S. E. Pautler, and M. D. Gass, "A long-term follow-up of choroidal osteoma," Archives of Ophthalmology, vol. 116, no. 10, pp. 1337–1341, 1998.
[3] C. L. Shields, H. Sun, H. Demirci, and J. A. Shields, "Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma," Archives of Ophthalmology, vol. 123, no. 12, pp. 1658–1666, 2005.
[4] D. J. Browning, "Choroidal osteoma: observations from a community setting," Ophthalmology, vol. 110, no. 7, pp. 1327–1334, 2003.
[5] J. D. M. Gass, R. K. Guerry, R. L. Jack, and G. Harris, "Choroidal osteoma," Archives of Ophthalmology, vol. 96, no. 3, pp. 428–435, 1978.
[6] C. L. Shields, B. Perez, M. A. Materin, S. Mehta, and J. A. Shields, "Optical coherence tomography of choroidal osteoma in 22 cases: evidence for photoreceptor atrophy over the decalcified portion of the tumor," Ophthalmology, vol. 114, no. 12, pp. e53–e58, 2007.
[7] D. L. Morrison, L. E. Magargal, D. R. Ehrlich, R. E. Goldberg, and E. Robb-Doyle, "Review of choroidal osteoma: successful krypton red laser photocoagulation of an associated subretinal neovascular membrane involving the fovea," Ophthalmic Surgery, vol. 18, no. 3, pp. 299–303, 1987.
[8] S. J. Rose, J. F. Burke, and R. J. Brockhurst, "Argon laser photocoagulation of a choroidal osteoma," Retina, vol. 11, no. 2, pp. 224–228, 1991.
[9] B. S. Foster, J. P. Fernandez-Suntay, T. P. Dryja, F. A. Jakobiec, and D. J. D’Amico, "Surgical removal and histopathologic findings of a subfoveal neovascular membrane associated with choroidal osteoma," Archives of Ophthalmology, vol. 121, no. 2, pp. 273–276, 2003.
C. L. Shields, M. A. Materin, S. Mehta, B. T. Foxman, and J. A. Shields, “Regression of extrafoveal choroidal osteoma following photodynamic therapy,” *Archives of Ophthalmology*, vol. 126, no. 1, pp. 135–137, 2008.

M. Battaglia Parodi, S. da Pozzo, L. Toto, S. Saviano, and G. Ravalico, “Photodynamic therapy for choroidal neovascularization associated with choroidal osteoma,” *Retina*, vol. 21, no. 6, pp. 660–661, 2001.

R. J. Morris, V. V. Prabhu, P. K. Shah, and V. Narendran, “Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma,” *Indian Journal of Ophthalmology*, vol. 59, no. 5, pp. 394–396, 2011.

A. D. Singh, J. F. Talbot, P. A. Rundle, and I. G. Rennie, “Choroidal neovascularization secondary to choroidal osteoma: successful treatment with photodynamic therapy,” *Eye*, vol. 19, no. 4, pp. 482–484, 2005.

P. Blaise, E. Duchateau, Y. Comhaire, and J. Rakic, “Improvement of visual acuity after photodynamic therapy for choroidal neovascularization in choroidal osteoma,” *Acta Ophthalmologica Scandinavica*, vol. 83, no. 4, pp. 515–517, 2005.

S. Sharma, N. Sribhargava, and M. P. Shanmugam, “Choroidal neovascular membrane associated with choroidal osteoma (CO) treated with trans-pupillary thermo therapy,” *Indian Journal of Ophthalmology*, vol. 52, no. 4, pp. 329–330, 2004.

D. Shukla, R. G. Tanawade, and K. Ramasamy, “Transpupillary thermotherapy for subfoveal choroidal neovascular membrane in choroidal osteoma,” *Eye*, vol. 20, no. 7, pp. 845–847, 2006.

M. Wagner-Schuman, A. M. Dubis, R. N. Nordgren et al., “Race- and sex-related differences in retinal thickness and foveal pit morphology,” *Investigative Ophthalmology and Visual Science*, vol. 52, no. 1, pp. 625–634, 2011.

H. Ahmadieh and N. Vafi, “Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin),” *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 245, no. 11, pp. 1731–1733, 2007.

R. Narayanan and V. A. Shah, “Intravitreal bevacizumab in the management of choroidal neovascular membrane secondary to choroidal osteoma,” *European Journal of Ophthalmology*, vol. 18, no. 3, pp. 466–468, 2008.

C. L. Shields, P. F. Salazar, H. Demirici, W. E. Benson, and J. A. Shields, “Intravitreal bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization overlying choroidal osteoma,” *Retinal Cases and Brief Reports*, vol. 2, pp. 18–20, 2008.

W. K. Song, H. J. Koh, O. W. Kwon, S. H. Byeon, and S. C. Lee, “Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma,” *Acta Ophthalmologica*, vol. 87, no. 1, pp. 100–101, 2009.

M.-H. Song and Y.-J. Roh, “Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to choroidal osteoma,” *Eye*, vol. 23, no. 8, pp. 1745–1746, 2009.

S. Rao and R. C. Gentile, “Successful treatment of choroidal neovascularization complicating a choroidal osteoma with intravitreal bevacizumab,” *Retinal Cases and Brief Reports*, vol. 4, no. 4, pp. 303–305, 2010.

G. S. Ayachit, N. Pandey, and V. Dwivedi, “Choroidal osteoma with CNVM—successful treatment with intravitreal Bevacizumab,” *Saudi Journal of Ophthalmology*, vol. 25, no. 2, pp. 199–202, 2011.

M. Kubota-Taniai, T. Oshitari, M. Handa, T. Baba, J. Yotsukura, and S. Yamamoto, “Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma,” *Clinical Ophthalmology*, vol. 5, no. 1, pp. 1051–1055, 2011.

M. Salehipour, N. Vafi, A. Doozande, and M. Yaseri, “Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration,” *Journal of Ophthalmic and Vision Research*, vol. 5, no. 1, pp. 10–19, 2010.

Z. H. Y. Wu, M. Y. Y. Wong, and T. Y. Y. Lai, “Long-term follow-up of intravitreal ranibizumab for the treatment of choroidal neovascularization due to choroidal osteoma,” *Case Reports in Ophthalmology*, vol. 3, no. 2, pp. 200–204, 2012.

M. V. Carle, T. G. Chu, D. Liao, and D. S. Boyer, “Successful use of anti-VEGF treatment for subretinal hemorrhage and fluid in a young patient with choroidal osteoma,” *Ophthalmic Surgery, Lasers and Imaging*, vol. 45, pp. 169–171, 2014.

M. K. Erol, D. T. Coban, B. B. Ceran, and M. Bulut, “Retinal pigment epithelium tear formation following intravitreal ranibizumab injection in choroidal neovascularization secondary to choroidal osteoma,” *Cutaneous and Ocular Toxicology*, 2014.